Skip to main content
. Author manuscript; available in PMC: 2014 Dec 3.
Published in final edited form as: J Cell Mol Med. 2014 Jan 23;18(4):685–697. doi: 10.1111/jcmm.12217

Figure 3. Enhanced fibroblast and myofibroblast cells in response to CD34+ cell therapy.

Figure 3

Immunofluorescence mediated detection of (A) fibroblast (SM22-α), and (B) myofibroblast (alpha smooth muscle actin, α-SMA) cells in the wound bed of animals received CD34+ cells or without cells as a control at various time points of therapy.